Demographic and laboratory data
| HC volunteers (n=21) | Patients with FD (n=24) | ||
|---|---|---|---|
| LG21 treatment | |||
| Before | After | ||
| Age, years | 42 (35–50)* | 44 (36–50) | |
| Male/female | 14/7 | 12/12 | |
| FSSG score | |||
| Epigastric pain-like (0–28) | 0 (0–1.0) | 12.5 (7.8–15.0)† | 4.0 (3.0–6.3)‡ |
| Postprandial distress-like (0–20) | 1.0 (1.0–2.0) | 15.0 (11.0–17.3) † | 7.2 (2.9–9.3)‡ |
| GF | |||
| Volume (mL) | 20.8±6.2§ | 22.2±9.0 | 18.7±9.4 |
| pH | 1.7 (1.6–1.9) | 1.7 (1.5–2.4) | 1.9 (1.6–3.8)‡ |
| No. of cultured bacteria (Log10 CFU/mL) | 1.5 (0–2.6) | 2.5 (1.3–4.0) | 3.8 (1.7–6.8) |
| Bile acids (+ve/−ve subjects) | 7/14 | 16/8† | 16/8 |
| (μM) | 0 (0–50.0) | 35.0 (0–157.5)† | 35.0 (0–75.0) |
| Bilirubin (+ve/−ve subjects) | 1/20 | 6/18 | 2/22 |
*Median (IQR).
†p<0.05 between HC and FD before treatment.
‡p<0.05 between before and after LG21 treatment.
§Mean±SD.
CFU, colony-forming units; FD, functional dyspepsia; FSSG, frequency scale for symptoms of gastroesophageal reflux disease; GF, gastric fluid; HC, healthy control.